Rankings
▼
Calendar
TNGX Q4 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$42M
Net Income
-$39M
EPS (Diluted)
$-0.30
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$30M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$399M
Total Liabilities
$53M
Stockholders' Equity
$346M
Cash & Equivalents
$112M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$4M
-100.0%
Gross Profit
$0
$4M
-100.0%
Operating Income
-$42M
-$41M
-2.3%
Net Income
-$39M
-$38M
-2.9%
← FY 2025
All Quarters